Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis
- 8 December 2011
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 73 (1), 55-65
- https://doi.org/10.1111/j.1365-2125.2011.04050.x
Abstract
Infliximab, an anti-tumour necrosis factor α monoclonal antibody, has profoundly modified the treatment of several inflammatory diseases. The objective was to assess the influence of methotrexate on the variability of infliximab pharmacokinetics and concentration-effect relationship in axial ankylosing spondylitis (AAS) patients. Twenty-six patients with AAS were included in a prospective study. They were treated by infliximab 5 mg kg⁻¹ infusions at weeks 0, 2, 6, 12 and 18. Infliximab concentrations were measured before, and 2 and 4 h after each infusion, and at each intermediate visit (weeks 1, 3, 4, 5, 8, 10 and 14). Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was measured at each visit. Infliximab pharmacokinetics was described using a two-compartment model with first-order distribution and elimination constants. A population approach was used. Infliximab pharmacodynamics was described using the area under the BASDAI curve. A total of 507 blood samples and 329 BASDAI measurements were collected. The following pharmacokinetic parameters were obtained (interindividual coefficient of variation): volumes of distribution for the central compartment = 2.4 l (9.6%) and peripheral compartment = 1.8 l (26%), systemic clearance = 0.23 l day⁻¹ (22%) and intercompartment clearance = 2.3 l day⁻¹. Methotrexate influenced neither pharmacokinetic nor BASDAI variability. Using the present dosage, the clinical efficacy of infliximab is only weakly influenced by its serum concentrations. The results do not support the combination of methotrexate with infliximab in ankylosing spondylitis.This publication has 36 references indexed in Scilit:
- Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitisScandinavian Journal of Rheumatology, 2010
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical Pharmacology, 2009
- Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control studyArthritis Care & Research, 2009
- Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formationAnnals Of The Rheumatic Diseases, 2007
- No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trialAnnals Of The Rheumatic Diseases, 2007
- A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumabBritish Journal of Clinical Pharmacology, 2007
- Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX SoftwareJournal of Pharmacokinetics and Pharmacodynamics, 2007
- Clinical Pharmacokinetics and Use??of??InfliximabClinical Pharmacokinetics, 2007
- Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2005
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984